D. Boral Capital Reiterates “Buy” Rating for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $10.00 price target on the medical research company’s stock.

Several other equities analysts have also recently issued reports on CTSO. HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th. StockNews.com began coverage on Cytosorbents in a research report on Monday. They issued a “hold” rating for the company. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Trading Down 1.0 %

NASDAQ CTSO opened at $1.04 on Monday. The company has a market capitalization of $56.87 million, a price-to-earnings ratio of -2.89 and a beta of 0.57. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.59. The firm’s fifty day moving average price is $0.92 and its 200 day moving average price is $1.03. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58.

Institutional Trading of Cytosorbents

Several large investors have recently bought and sold shares of CTSO. Atomi Financial Group Inc. purchased a new stake in shares of Cytosorbents in the 3rd quarter worth about $51,000. Geode Capital Management LLC boosted its stake in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares during the last quarter. Finally, Sargent Investment Group LLC raised its stake in Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.